The bcl-2 gene is translocated into the Ig loci in about 80% of human follicular lymphomas and in 10% of B-type chronic lymphocytic leukemias (B-CLL), resulting in a high level of expression. We have compared the expression of bcl-2 transcripts and protein in B-CLL cells in their normal equivalent CD5+ B cells and in normal B-cell populations representative of different in vivo and in vitro stages of activation and proliferation. We report here that bcl-2 was expressed in 11 of 11 cases of CD5+ B-CLL clones, contrasting with the absent expression in normal CD5+ B cells. Activation of 173 and 183 B-CLL cells by phorbol esters (12-0-tetradecanoylphorbol-13-acetate [TPA]) t o IgM secretion without concomitant DNA synthesis resulted in a rapid but transient downregulation of bcl-2 expression. In contrast, the reduction of bcl-2 at both the messenger RNA and protein levels was sustained after mitogenic stimulation, suggesting that bcl-2 expression the relatively long-lived B-CLL cells, we studied the expression of bcl-2 in fresh B-CLL cells obtained from a number of patients as compared with normal CD5+ B lymphocytes. We also examined the bcl-2 expression during in vitro activation, proliferation, and differentiation of B-CLL cells and in purified normal B-cell populations, germinal center (GC) B blasts, and B mantle cells, representative of different stages of in vivo intrafollicular B-cell activation and proliferation.
The bcl-2 gene is translocated into the Ig loci in about 80% of human follicular lymphomas and in 10% of B-type chronic lymphocytic leukemias (B-CLL), resulting in a high level of expression. We have compared the expression of bcl-2 transcripts and protein in B-CLL cells in their normal equivalent CD5+ B cells and in normal B-cell populations representative of different in vivo and in vitro stages of activation and proliferation. We report here that bcl-2 was expressed in 11 of 11 cases of CD5+ B-CLL clones, contrasting with the absent expression in normal CD5+ B cells. Activation of 173 and 183 B-CLL cells by phorbol esters (12-0-tetradecanoylphorbol-13-acetate [TPA]) t o IgM secretion without concomitant DNA synthesis resulted in a rapid but transient downregulation of bcl-2 expression. In contrast, the reduction of bcl-2 at both the messenger RNA and protein levels was sustained after mitogenic stimulation, suggesting that bcl-2 expression HE bcl-2 GENE codes for a 25-Kd located at T the inner mitochondrial membrane? The gene is translocated into the heavy chain Ig locus in a high proportion of human lymphomas of follicular center cell p h e n~t y p e~-~ and into the light chain Ig loci in some cases of B-cell chronic lymphocytic leukemia (B-CLL)? resulting in a high constitutive expression of bcl-2 messenger RNA (mRNA) and pr~tein.*,~-~l The knowledge of the role of bcl-2 in normal and malignant lymphopoiesis is fragmentary. Normal resting peripheral B cells do not express bcl-2, but the gene is induced after mitogenic stimulation.10,12 Introduction of the human bcl-2 gene into murine B-cell precursors results in increased survival in the absence of otherwise essential growth f a~t o r s~~J~ and high-level expression of bcl-2 confers a selective growth advantage to Epstein-Barr virus (EBV)-infected B c e l l~.~~J~ In addition, transgenic mice that possess a bcl-2-Ig minigene, representing the fusion product found at the chromosomal breakpoint of human follicular lymphomas, develop an expanded compartment of mature polyclonal B cells, predominantly of follicular origin, that are 99% in the Go phase of the cell cycle. 17 These findings show that the bcl-2-Ig transgene is able to confer a survival advantage to mature resting B cells that, as a consequence, leads to their selective expansion. In accordance with this view, overexpression of bcl-2 was recently shown to block programmed cell death (apoptosis) in murine FL5.12 pro-B lymphocytes.3 Constitutive bcl-2 expression, thus, might cooperate with the activation of the c-myc gene in the multistep development of lymphoInterestingly, among human B-cell malignancies, B-CLL is characterized by the progressive accumulation of mature CD5+ resting B cells.20 More than 99% of the circulating malignant cells are in the Go phase of the cell cycle.21 We and others have previously shown that B-CLL cells can be activated in vitro to enter the cell cycle and, subsequently, to high levels of Ig secretion and/or DNA synthesis in response to certain stim~li.~*-25
Considering a possible role of bcl-2 in the maintenance of the relatively long-lived B-CLL cells, we studied the expression of bcl-2 in fresh B-CLL cells obtained from a number of patients as compared with normal CD5+ B lymphocytes.
We also examined the bcl-2 expression during in vitro activation, proliferation, and differentiation of B-CLL cells and in purified normal B-cell populations, germinal center (GC) B blasts, and B mantle cells, representative of different stages of in vivo intrafollicular B-cell activation and proliferation.
MATERIALS AND METHODS
Cells. CD5+ malignant B lymphocytes were obtained from nine patients with B-CLL (seven males and three females, age 56 to 67 years). According to the Rai's staging system?6 two patients were in stage 0-1, three in stage 11, two in stage 111, and two in stage IV. None of the patients had received chemotherapy in the 4 months preceding this study. Peripheral blood lymphocytes (PBL) were separated from the PB of the patients on Ficoll-Hypaque (FH). T lymphocytes were removed by two cycles of rosetting with sheep red blood cells (SRBC) when the proportion of slg-, CD3+ cells exceeded 5%.
I73 and I83 are well-characterized selected B-CLL clones.27 Tonsils (two samples) from adults undergoing tonsillectomy after antibiotic treatment were teased with blunt forceps. Cell CD5+ normal B lymphocytes were purified from cord blood (two samples), as previously described.29
Cell lines used were the follicular lymphoma cell line Karpas 422, containing a t(14;18) involving the bcl-2 locusM; the Burkitt's lymphoma cell line Daudi"; the EBV-immortalized B-CLL cell Cell cultures and inductions. I73 and I83 B-CLL cells were thawed, washed with RPMI-1640 medium, and cultured at a concentration of 2 x 106/mL in RPMI-1640 medium supplemented with 10% fetal calf serum (FCS), 2 mmol/L glutamine, 100 IU/mL penicillin, 100 pg/mL streptomycin, 50 pg/mL gentamycin in the presence of different stimuli. All cell lines used were cultured in RPMI-1640 supplement as above. Heat-inactivated, formalin-fixed Staphylococcus aweus Cowan I (SAC) bacterial wall was used at a final concentration of 0.1%; the phorbol ester 12-0-tetradecanoylphorbol-13-acetate (TPA, Sigma, St Louis, MO, P8139) at a concentration of 1.6 x lo-' mol& and B-cell stimulatory factor (BSF) from the T-cell hybridoma (MP6)33 at a concentration of 25% vol/vol. The major active component in BSF-MP6 has recently been identified as thi0redoxin.3~ Recombinant interleukin-2 (rIL-2; Amersham, Buckinghamshire, UK, specific activity, 7 x 106 U/mg) was used at the concentration of 100 U/mL; rIL-4 (Genzyme, Boston, MA, specific activity, 108 U/mg) at the concentration of 100 U/mL; and recombinant tumor necrosis factor-a (rTNF-a; kind gift of Dr G.R. Adolf, EmstBoehringer Inst, Vienna, Austria; specific activity, 6 x lo7 U/mg) at the concentration of 100 ng/mL.
The DNA synthesis was determined by incubating cells in 0.2 mL cultures with 1 pCi of 3H-thymidine (3H-TdR DuPont, Boston, MA, specific activity, 6.7 Ci/mmol) for the last 24 hours of the 6-day incubation.
Phenotype.
Induced differentiation was evaluated by morphologic examination of May-Griinwald-Giemsa-stained cytospin slides and by measuring the amount of secreted IgM using the enzyme-linked immunosorbent assay (ELISA) technique.
High molecular weight (MW) DNA was isolated using standard methods, digested with restriction enzymes, size fractionated in 0.8% agarose gels, and transferred to nitrocellulose filters. Blots were hybridized with 32P-labeled probes, washed in 0.5% sodium dodecyl sulfate (SDS), 2X SSC (1X SSC = 0.15 mol/L NaCI, 0.015 mol/L NaCitrate, pH 7.0) at 65T, and autoradiographed (Kodak XAR-5; Eastman Kodak, Rochester, NY) at -70°C. The filters were reused with different probes after removal of the previous signal by washing with 0.1X SSC/ 0.1% SDS at 100°C. The bcl-2 probes used were a 2.8-kb EcoRIHind111 genomic fragment corresponding to the major breakpoint region (MBR) in the untranslated 3' end of the bcl-2 gene and a 1.6-kb EcoRI-EcoRI fragment corresponding to the 5' end breakpoint region35 (kind gifts of Dr Y. Tsujimoto, The Wistar Institute of Anatomy and Biology, Philadelphia, PA).
Total cellular RNA was isolated by the lithium chloridehrea procedure?6 Denatured total RNA samples (15 pg/well) were fractionated on a 1% formaldehyde-containing agarose gel, transferred to a nitrocellulose filter, and hybridized with 32P-labeled probes in 3X SSC, 0.2% SDS, 1X Denhardt's solution, 100 pg/mL denatured salmon sperm DNA, and 50% formamide, at 42°C for 18 hours. The filters were washed twice under stringent conditions (0.1X SSC, 0.1% SDS) at 54°C and exposed to Kodak X-OMAT films for 1 to 14 days at -80°C. The bcl-2 probe used was the MBR probe. The actin probe was a mouse a-actin cDNA clone, ~91.3'
Immunocytochemistry. The cells were cytocentrifuged, dried for 30 minutes, and then fixed in acetone for 10 minutes. After three washes in phosphate-buffered saline (PBS), the slides were incubated for 1 hour with specific antibodies. The antibodies used were monoclonal anti-bcl-2 antibodies:* diluted 1:lO (kindly provided by Dr David Mason, John Radcliffe Hospital, Headington, UK), and monoclonal anti-Ki67 antibodies (Dakopatts; cat. no. M772), diluted 1:lO. R-anti-M Ig antibodies were used as a second layer. The subsequent procedures used Vectastain peroxidase ABC reagents (Vector Laboratories Inc, Burlingame, CA) for the Ki67 staining and APAAP (Dakopatts) for the bcl-2 staining.
The peroxidase activity was visualized by 3-amino-9-ethylcarbazol and the alkaline phosphatase activity by Naphtol AS-MX phosphate/Fast blue.
Cells were lysed in a buffer containing 25 mmol/L Tris, pH 8, 1% NP40, 0.5% desoxycholate, 144 mmol/L NaCI, 0.1% SDS, 5 mmol/L dithiothreitol (DTT), 1% trasylol, 10 mmol/L iodoacetamide, and 0.5 mmol/L phenylmethylsulfonyl fluoride (PMSF) at 4°C. After sonication three times for 15 seconds, the lysates were cleared by centrifugation at 17 K for 30 minutes. The extract (200 Kgllane) was boiled for 4 minutes in sample buffer (0.1 mol/LTris, pH 6.8,3% SDS, 5% p-mercaptoethanol), run on a 13% SDS/polyacrylamide gel, and subsequently electrotransferred overnight in transfer buffer (25 mmol/L Tris, pH 7.4, 20 mmol/L glycine, 20% methanol, and 0.1% SDS) to a nitrocellulose filter. The filter was preblocked in 2% nonfat milk, 0.05% Tween 20 in PBS for 1 hour before overnight incubation with antidcl-2 antibodies diluted 1:50. Alkaline phosphataseconjugated goat anti-M Ig (Bio-Rad Laboratories, Richmond, CA) diluted 1:3,000 was used as a second layer and the proteins were visualized by 5-bromo-4-chloro-3-indolyl phosphate (BCIP) and p-nitro blue tetrazolium (NBT; Bio-Rad).
Southern blot analysis.
Northern blot analysis.
Western blot analysis.
bel-2 EXPRESSION IN B-CLL CELLS

2983
RESULTS
B-CLL cells were purified from nine patients with CLL, representative of different clinical stages of the disease. The cells from all patients coexpressed weak surface (s) monoclonal Ig, CD5, and CD19 as evidenced by IF. None of the cases showed bcl-2 rearrangement within the MBR and the 5' end breakpoint region (data not shown). To investigate the expression of bcl-2 mRNA, total RNA prepared from the B-CLL tumors was subjected to Northern blot analysis using a 32P-labeled bcl-2 probe. As shown in Fig lA, bcl-2 transcripts were observed in all nine of the fresh B-CLL samples analyzed, the high M W 8.5-kb transcript usually being the most abundant. After densitrometrical scanning, the amount of bcl-2 mRNA was normalized to the amount of actin mRNA, used as a reference gene, and to the amount of total RNA loaded as visualized by EtBr staining. Some differences in bcl-2 mFWA expression were observed in the different B-CLL samples, but these seemed to be unrelated both to the clinical stage and to the number of white blood cells (WBC).
The expression of bcl-2 is rapidly but transiently downregulated in I73 B-CLL cells after TPA induction. Because bcl-2 has been reported to be induced during activation of normal resting B and T lymphocytes,10J2 we investigated the expression of bcl-2 mRNA in B-CLL cells activated by TPA. We selected for this experiment one B-CLL clone, 173, which responds to TPA by transition from Go to GI and differentiation into IgM-secreting lymphoblasts/plasmablasts in the absence of DNA synthesis.*' Northern blot analysis showed that the steady state level of bcl-2 transcripts in I73 was rapidly downregulated in response to TPA. The level decreased within 1 hour, and reached a minimum (35% of control level) at 3 hours after stimulation (Fig lB) , whereas only minimal changes in the amount of actin mRNA were observed. The level of bcl-2 mRNA subsequently increased and was elevated fourfold as compared with the control cells at 12 and 72 hours postinduction. Also, the level of actin mRNA increased at late time points concomitant with the blast trasformation, as previously reported.39 The expression of bcl-2 mRNA late after induction was comparable to that observed in Karpas 422 follicular lymphoma cells, carrying a 14;18 translocation of the bcl-2 locus.31 No bcl-2 mRNA was detectable in Daudi Burkitt's lymphoma cells.
The expression of bcl-2 mRNA is reduced after mitogenic stimulation of B-CLL cells. We have previously described that the B-CLL clone I83 is inducible to activation and subsequent differentiation in the absence or presence of DNA synthesis using selected B-cell activators and cytokines.",= To further investigate the relationship of bcl-2 expression to activation, proliferation, and differentiation in B-CLL cells, I83 cells were stimulated for 6 days by different inducers according to five different protocols:
IL-2, TPA + BSF-MP6 + IL-4, and SAC + BSF-MP6 + IL-2 + IL-4. As shown in Table 1 The expression of bcl-2 mRNA 6 days after induction was evaluated by Northern blot analysis. Figure 1C shows that the reduction of bcl-2 expression was particularly strong in response to SAC + BSF-MP6 + IL-2 exposure, but also after stimulation by TPA + BSF-MP6 + IL-4. Densitometric scanning and normalization to the amount of actin mRNA and to the amount of loaded total RNA suggested approximate fivefold and threefold reductions, respectively. In contrast, only minor reductions in response to TPA and to SAC + BSF-MP6 + TNF-a, and no change after SAC + BSF-MP6 + IL-2 + IL-4 treatment, were observed. The results thus suggest that bcl-2 is primarily reduced after exposure to factors that induce a high DNA synthesis in I83 cells.
The amount of bcl-2protein is reduced in I83 B-CLL cells during induced proliferation. To investigate whether the changes in bcl-2 mRNA expression in I83 after mitogenic stimulation were reflected at the protein level, cell extracts obtained from stimulated 183 cells were subjected to a Western blot analysis. As shown in Fig 2, Because stimulation of I83 B-CLL cells according to the various protocols results in the development of a rather homogenous population of small resting B lymphocytes into a heterogenous population of cells at different stages of activation and differentiation with or without concomitant we asked whether bcl-2 was preferentially expressed in certain subpopulations of cells after stimulation. In particular, we wanted to study the amount of bcl-2 in the proliferating cells. Therefore, we examined the expression of bcl-2 and the proliferation-associated nuclear antigen Ki67 in individual cells by immunocytochemical doublelabeling.
Expression of bcl-2 at the single cell level. Figure 3A shows an intense bcl-2 staining in the sparse cytoplasm of untreated I83 cells. Also, cells treated by TPA for 6 days showed an intense cytoplasmic staining, distributed rather homogenously within the population (Fig 3B) .
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In contrast, cells stimulated by SAC + BSF-MP6 + IL-2 exhibited a significantly reduced expression of bcl-2, particularly among the Ki-67-positive B blasts, but also apparent in a substantial part of the Ki-67-negative population, usually resembling B blasts or activated lymphocytes ( Fig  3C) . Although most Ki-67-positive cells exhibited a low bcl-2 expression, occasional cells, usually with plasmablast morphology, expressed both Ki-67 and bcl-2 at a high level (Fig 3C) . After TPA + BSF-MP6 + IL-4 inductions, which result in a pronounced morphologic and functional differentiation of I83 ~ells,z.3~ a more complex distribution of bcl-2 and Ki-67 expression was found. As in SAC + BSF-MP6 + IL-2-stimulated cells, bcl-2 was expressed in the small-to medium-sized lymphocytes and generally had low expres-K D l 2 3 4 5 6 7 8 4 6 1
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14 - sion in the larger Ki-67-positive B blasts, whereas the expression in middle-sized lymphocytes was more heterogeneous. However, bcl-2 staining was also often intense in the more differentiated TPA + BSF-MP6 + IL-&induced cells, resembling plasmablasts (Fig 3D) . Corinna I1 cells, representing EBV-immortalized CLL cells, showed a very weak bcl-2 staining (Fig 3E) . Because B-CLL cells are CD5+, we first compared the bcl-2 mRNA level in B-CLL with that of normal CD5+ B cells. Isolated cord blood CD5+ B cells were sIgM+, sIgD+, CD19+, CD20+, HLADR+ and, in a small proportion (20% to 30%), CD23+ and CD25+ (data not shown). As shown in Fig lA, normal CD5+ B cells from cord blood did not express bcl-2 transcripts.
We next analyzed the bcl-2 expression in normal follicular B cells. The purified follicular B cells were separated into M-B cells and GC-B blasts by their differential reactivity with the RFA-2 antibody. GC-B blasts were sIgM+ (>go%), sIgD-(<5%), CD38+ (> 80%), CD10+ (40%), whereas the non-GC-M-B cells were sIgM+, sIgD+, CD19+, CD20+, HLA-DR+, CD10-, CD38-(data not shown). As shown in Fig 4, the GC-B blasts did not express the message for bcl-2. Neither was cytoplasmic bcl-2 staining observed in these cells using the anti-bcl-2 antibody (data not shown). On the contrary, both bcl-2 message (Fig 4) and the cytoplasmic bcl-2 staining (not shown) were observed in the vast majority (>80%) of resting B mantle cells. bcl-2 mRNA was not detected in total tonsil tissue, but was expressed in monocytes. PBL stimulated with phytohemagglutinin (PHA) + TPA were used as a positive control.
Expression of bcl-2 in normal B-cellpopulations.
DISCUSSION
The observation that bcl-2/Ig transgenic mice develop an expanded compartment of mature B cells that are 99% in the Go phase of the cell cycle17 led us to investigate the expression of bcl-2 in B-CLL, which is characterized by the relentless accumulation of mature resting B cells.20~21~24 We have compared here the expression of bcl-2 transcripts and protein in B-CLL cells, in normal CD5+ B cells, and in normal B-cell populations representative of different in vivo stages of activation and proliferation. In two selected B-CLL cl0nes,2~ the expression of bcl-2 mRNA and protein has been evaluated also after in vitro treatment with different protocols of activation to growth andlor differentiation. The results show: (1) that malignant CD5+ B-CLL cells express high levels of bcl-2 mRNA and protein, comparable with the levels observed in cells of the Karpas 422 cell line containing a translocated bcl-2 gene, while in normal CD5+ B cells bcl-2 mRNA cannot be detected ( Figs  1 and 2) ; and (2) that the expression of bcl-2 in B-CLL cells is downregulated by mitogenic stimulation.
In agreement with recently reported data,38p41 all B-CLL cases expressed bcl-2. The level of expression seems unrelated to the clinical stage of the patients and does not reflect a rearrangement of bcl-2, which has been shown to be a rare
The fact that the bcl-2 gene is translocated into the Ig light chain loci in approximately 10% of CLL However, we have shown that in two selected clones of B-CLL the expression of bcl-2 is not constitutive, but can be modulated. bcl-2 is rapidly but transiently downregulated in both I73 and I83 B-CLL clones exposed to TPA (Fig 11. 
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much less expressed in the B blasts (Fig 3) , which comprise most of the Ki-67-positive, proliferating cell elements at an intermediate stage of B-cell differentiatioma This finding is in agreement with our recent observation that bcl-2 is expressed in normal plasma cells of the bone marrow and the lymph node medulla and in human myeloma cell lines." However, in contrast to Pezzella et a1,38 we have found occasional cells that coexpress bcl-2 and Ki-67 at a high level (Fig 3C) . These were usually morphologically more mature than B blasts and it is presently unclear whether they still progress into the cell cycle. Second, the bcl-2 level observed in the exponentially growing lymphoblastoid cell line (LCL) and B-CLL cell line Corinna I and I1 is low (Fig   2) . In SAC + BSF-MP6 + IL-2-and TPA + BSF-MP6 + IL-&treated CLL cells the small-to middle-sized, usually Ki-67-negative cells that morphologically resemble activated lymphocytes often exhibit low bcl-2 expression. This contrasts with the behavior of cells of similar morphology in TPA-treated cultures, which uniformly show higher levels of bcl-2. We speculate that B cells determined to traverse the cell cycle into S-phase, rather than to enter a differentiation pathway in the absence of proliferation, will downregulate bcl-2 at an early stage, before becoming Ki-67 positive. Downregulation of bcl-2 expression in B cells could thus be related to the choice of entering a self-renewal pathway and mirror the myc regulation operating when the cell choice is toward the differentiation pathway. Furthermore, stimulated CD5+ B cells (both normal and malignant) acquire similarities with GC-B cells both at the phenotypic levelz9 and with respect to factor requirement for growth in vitr0.4~ Our observation that CD5+ normal B cells from cord blood, which exhibit an activated phenotype, do not express bcl-2 may also support this notion.
On this basis, our observations led us to formulate the hypothesis that the high expression of bcl-2 in B-CLL cells reflects their affiliation to a long-lived memory type of B cell (Fig 5) located in the mantle zone of lymphoid follicles.
This hypothesis is well in keeping with the transgenic mouse model, in which it has been shown that bcl-2 influences the generation and maintenance of B-cell memory.50 It is thus possible that B-CLL may represent a tumor characterized by an abnormal balance in the production of terminally differentiated cells versus memory cells that may be used as a model system for studying memory B cell behavior. Further investigation is required to establish the role of CD5+ normal B cells in this scenario.
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